Northwestern University Feinberg School of Medicine

Department of Physical Medicine & Rehabilitation

Clinical Trials

Clinica research under the direction of the Department of Physical Medicine and Rehabilitation is conducted through Northwestern University Feinberg School of Medicine. Below you'll find our current clinical trial, including investigator and contact information.

Find additional clinical trials information related to physical medicine and rehabilitation via the Shirley Ryan AbilityLab's clinical trials listing.

Feinberg Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about all our work via the Feinberg Office of Research Clinical Trials page. Search for trials by disease or condition.

Trials
Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee
The purpose of this study is to compare the long-term joint safety and efficacy (pain relief) of the investigational study drug, tanezumab compared to non-steroidal anti inf…
The purpose of this study is to compare the long-term joint safety and efficacy (pain relief) of the investigational study drug, tanezumab compared to non-steroidal anti inflammatory drugs (NSAIDs) in subjects with osteoarthritis of the hips or knees.
Schnitzer, Thomas JSchnitzer, Thomas J
NCT02528188 STU00201068
More Info

For more information on this study please contact us:

Swiostek, Irmina 312 503 4163
A Phase 3 Study of Tanezumab for Chronic Low Back Pain
This study will investigate the efficacy and safety of tanezumab 5 mg and 10 mg administered by subcutaneous injection seven times at 8 week intervals (56 weeks). The primary objective of this study is to evaluate the …
This study will investigate the efficacy and safety of tanezumab 5 mg and 10 mg administered by subcutaneous injection seven times at 8 week intervals (56 weeks). The primary objective of this study is to evaluate the effectiveness of tanezumab 10 mg and 5 mg compared to placebo for the treatment of chronic low back pain. Secondary objectives are to evaluate the long-term safety and effectiveness of tanezumab 10 mg and 5 mg compared to placebo for the treatment of chronic low back pain. In addition, the study will evaluate the effectiveness and long term safety profile of tanezumab treatment for chronic low back pain compared to tramadol Prolonged Release (PR), a medication commonly utilized for the treatment of chronic low back pain.
Schnitzer, Thomas JSchnitzer, Thomas J
  • Map it 710 N. Lake Shore Dr. Abbott Hall
    Chicago, IL
STU00201593
More Info

For more information on this study please contact us:

Swiostek, Irmina 312 503 4163
COAST-1: Clinical Knee Osteoarthritis Symptom Treatment 1 Study A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Knee Osteoarthritis Associated with Bone Marrow Lesions.
This study…
This study is designed to determine the efficacy and safety of Disodium Zoledronate Tetrahydrate in reducing pain in subjects with knee osteoarthritis. Males of 50 years of age or older and post-menopausal females with knee pain or newly diagnosed osteoarthritis of the knee may be eligible to participate.
Males of 50 years of age or older and post-menopausal women may be eligible to participate.
Schnitzer, Thomas JSchnitzer, Thomas J
  • Map it 710 N. Lake Shore Dr. Abbott Hall
    Chicago, IL
NCT02746068 STU00202310
More Info

For more information on this study please contact us:

Rivera, Natalie 312 503 3806
Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
Approximately 10,000 patients will participate in this study to further characterize the safety profile of fasinumab and provide data on long-term exposure to provide efficacy data. I…
Approximately 10,000 patients will participate in this study to further characterize the safety profile of fasinumab and provide data on long-term exposure to provide efficacy data. In addition to their participation in the main study, approximately 800 patients will participate in a sub-study to characterize the onset of pain relief by fasinumab.
At least 18 yrs of age, BMI 39 or less, Osteoarthritis of the knee or hip, taking either Acetaminophen/Tylenol, NSAIDs or opioids at least 4 days a week over last month, fails (either inadequate pain relief, unable to take or refuses to take) Acetaminophen/Tylenol, NSAIDs, and opioids, no rheumatoid arthritis, no fibromyalgia, no symptoms of carpal tunnel syndrome in last 6 months, able to undergo an MRI, is not scheduled for a joint replacement in the next 1.5 yrs, no HIV, no Hepatitis, no sickle cell disease, no S-C disease, no S-beta thalassemia, no heart block, no cancer in last 5 yrs, no hospitalization for depression in last 5 yrs, no alcohol or substance abuse in last 5 yrs, no marijuana use for pain relief in last 6 months, if a female must not become pregnant or breastfeed during the study, and if a female of child-bearing potential must be willing to use contraception during study.
Schnitzer, Thomas JSchnitzer, Thomas J
  • Map it 710 N. Lake Shore Dr. Abbott Hall
    Chicago, IL
NCT02683239 STU00202672
More Info

For more information on this study please contact us:

Rivera, Natalie 312 503 3806
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF A DOSE TITRATION REGIMEN FOR THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE
The purpose of this research study is to compare the effects o…
The purpose of this research study is to compare the effects of the investigational study drug, tanezumab, with a placebo to find out if it is better for treating osteoarthritis. Tanezumab is an investigational drug. An investigational drug is one that is not approved for sale in this country. A placebo looks like the study drug but does not contain any drug. Researchers use a placebo to see if the study drug works better or is safer than not taking anything. Tanezumab is a monoclonal antibody (a type of protein made in the laboratory) that can bind to human nerve growth factor (NGF), which is involved with the feeling of pain. Elevated levels of NGF are also associated with inflammation, tissue damage, and arthritis. It is hoped that when tanezumab binds to NGF that it may reduce pain.
18 years or older, diagnosed with osteoarthritis of the hip or knee, currently experiencing pain in the hip or knee joint, not receiving adequate pain relief from current medications, no joint injections in the last 3 months, no surgeries to the joint in the last year, no carpal tunnel syndrome, no hepatitis or HIV.
Schnitzer, Thomas JSchnitzer, Thomas J
NCT02697773 STU00203439
More Info

For more information on this study please contact us:

Swiostek, Irmina 312 503 4163
Open-label safety trial of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS)
This study is designed to test the safety and effectiveness of neridronic acid in patients with complex regional pain syndrome (CRPS). This study is an "open label" trial so all participants …
This study is designed to test the safety and effectiveness of neridronic acid in patients with complex regional pain syndrome (CRPS). This study is an "open label" trial so all participants will receive treatment. There is no placebo involved. Males or females of 18 years or older that has been diagnosed with complex regional pain syndrome (CRPS), with moderate to severe pain in one limb (arm or leg) may be eligible. Participants must not have any planned invasive dental procedures (eg. tooth extractions) or history of significant dental issues or peridontal disease.
Male or female of 18 years or older that has been diagnosed with complex regional pain syndrome (CRPS), with moderate to severe pain in one limb (arm or leg). Participants must not have any planned invasive dental procedures (eg. tooth extractions) or history of significant dental issues or peridontal disease.
Schnitzer, Thomas JSchnitzer, Thomas J
  • Map it 710 N. Lake Shore Dr. Abbott Hall
    Chicago, IL
NCT02972359 STU00204323
More Info

For more information on this study please contact us:

Rivera, Natalie 312 503 3806
A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Pain Due to Osteoarthritis of the Knee or Hip
Approximately 3,640 patients will participate in this study to evaluate the efficacy of fasinumab compa…
Approximately 3,640 patients will participate in this study to evaluate the efficacy of fasinumab compared to placebo for the treatment of osteoarthritis pain.
At least 18 yrs of age, BMI 39 or less, Osteoarthritis of the knee or hip, taking NSAIDs at least 4 days a week over last month, fails (either inadequate pain relief, unable to take or refuses to take) Acetaminophen/Tylenol, NSAIDs, and opioids, must be able to take naproxen, no rheumatoid arthritis or other inflammatory joint disease, no fibromyalgia, no symptoms of carpal tunnel syndrome in last 6 months, able to undergo an MRI, is not scheduled for a joint replacement in the next 1.5 yrs, no HIV, no Hepatitis, no sickle cell disease, no S-C disease, no S-beta thalassemia, no heart block, no cancer in last 5 yrs, no hospitalization for depression in last 5 yrs, no alcohol or substance abuse in last 5 yrs, no marijuana use for pain relief in last 6 months, if a female must not become pregnant or breastfeed during the study, and if a female of child-bearing potential must be willing to use contraception during study.
Schnitzer, Thomas JSchnitzer, Thomas J
  • Map it 710 N. Lake Shore Dr. Abbott Hall
    Chicago, IL
NCT03161093 STU00205258
More Info

For more information on this study please contact us:

Swiostek, Irmina 312 503 4163
D-Cycloserine for the Treatment of Chronic, Refractory Low Back Pain
The purpose of this study is to evaluate the efficacy and safety of D-cycloserine versus placebo in relieving the signs and symptoms of patients with chronic lower back pain. This study will last for 26 weeks and will require approx…
The purpose of this study is to evaluate the efficacy and safety of D-cycloserine versus placebo in relieving the signs and symptoms of patients with chronic lower back pain. This study will last for 26 weeks and will require approximately 6 visits to the study clinic. There will be two groups in this study. You will have an equal chance of being in either group. One group will receive D-cycloserine in capsule form and one group will receive placebo in capsule form. All participants have to take two capsules every day, one in the morning and one in the evening. There will be a 1 in 2 chance of receiving placebo.
Must have a history of low back pain for a minimum of 6 months with or without signs and symptoms of radiculopathy
Male or female, age 18 years or older
Must be in generally stable health
Must have a smartphone that will allow downloading of the pain app
Must be willing to abstain from drinking alcohol during the course of the study.
If female, must be post-menopausal for at least one year or practicing an accepted, highly effective method of contraception or abstinence and plan to continue during the course of the study.
Schnitzer, Thomas JSchnitzer, Thomas J
  • Map it 710 N. Lake Shore Dr. Abbott Hall
    Chicago, IL
NCT00125528 STU00205398
More Info

For more information on this study please contact us:

Yip, Byron K. 312 503 4856